Hanson & Doremus Investment Management Purchases New Shares in AstraZeneca PLC $AZNCF

Hanson & Doremus Investment Management bought a new position in AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,009 shares of the company’s stock, valued at approximately $1,185,000.

A number of other large investors also recently modified their holdings of AZNCF. Hughes Financial Services LLC acquired a new position in shares of AstraZeneca during the fourth quarter valued at $34,000. Fairscale Capital LLC acquired a new stake in AstraZeneca in the fourth quarter worth about $37,000. Mascoma Wealth Management LLC acquired a new stake in AstraZeneca in the fourth quarter worth about $46,000. Aventus Investment Advisors Inc. bought a new stake in AstraZeneca during the 1st quarter worth about $46,000. Finally, Resources Management Corp CT ADV bought a new stake in AstraZeneca during the 4th quarter worth about $61,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

AZNCF opened at $187.10 on Tuesday. The firm has a 50 day simple moving average of $187.10 and a 200 day simple moving average of $186.10. AstraZeneca PLC has a fifty-two week low of $122.26 and a fifty-two week high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.